Kodak Pharmaceuticals Expands Product Portfolio with New Normal Saline Solution and U.S. Online Store
Eastman Kodak Company has announced the expansion of its KODAK PHARMACEUTICALS product portfolio with the addition of KODAK® Normal Saline, 0.9%, while also introducing a new U.S.-based online store designed to make purchasing pharmaceutical-grade products easier for customers. The developments represent another step in Kodak’s efforts to strengthen its presence in the pharmaceutical, biotechnology and life sciences markets by providing essential reagents manufactured domestically.
The newly introduced normal saline solution expands Kodak’s growing range of sterile, ready-to-use buffers and reagents. These products are manufactured at the company’s U.S.-based, FDA-registered current Good Manufacturing Practice (cGMP) facility, supporting its strategy of supplying customers with products designed for use in regulated environments.
Alongside the product launch, Kodak is making its pharmaceutical portfolio more accessible through a dedicated online purchasing platform. The store enables U.S. customers to browse available products, review specifications, access supporting documentation and place orders directly. By combining portfolio expansion with a streamlined purchasing experience, Kodak aims to improve convenience for pharmaceutical manufacturers, biotechnology companies and life science organizations.
Expanding the KODAK PHARMACEUTICALS Product Portfolio
The addition of KODAK Normal Saline, 0.9%, represents an important development in Kodak’s expanding range of pharmaceutical and laboratory products. Normal saline is an isotonic solution containing sodium chloride at a concentration of 0.9%. Solutions of this type are widely used in healthcare, laboratory and pharmaceutical settings, depending on their formulation, quality specifications and intended application.
Kodak’s new product extends its portfolio into sterile reagents intended to support laboratory and bioprocessing workflows. The company states that the solution is manufactured and aseptically filled in the United States, providing customers with information about its domestic production and manufacturing process.
The product is described as fully traceable and compliant with applicable United States Pharmacopeia (USP) requirements. These characteristics are important for organizations operating in regulated industries, where product specifications, documentation and traceability can play significant roles in quality management and supply-chain oversight.
For pharmaceutical and biotechnology customers, access to reliable reagents is an essential consideration in maintaining consistent processes. Manufacturing standards, product documentation and dependable sourcing can help organizations evaluate materials for their specific operational requirements. Kodak’s portfolio strategy focuses on supplying these customers with products that support their needs in regulated environments.
The expansion also reflects the company’s broader effort to build a portfolio of essential pharmaceutical ingredients and laboratory solutions. By adding normal saline to its existing offerings, Kodak is broadening the range of products available to customers through its pharmaceutical business.
U.S.-Based Manufacturing Supports Domestic Supply
Kodak is positioning its U.S.-based manufacturing operations as a central element of its pharmaceutical strategy. The company manufactures its growing portfolio of sterile, ready-to-use buffers and reagents at an FDA-registered cGMP facility in the United States.
Current Good Manufacturing Practice requirements provide a framework for maintaining appropriate manufacturing controls and product quality. For companies serving pharmaceutical and life science markets, these controls and the supporting documentation can be important factors in supplier evaluation and procurement decisions.
Domestic manufacturing can also offer customers greater visibility into product sourcing and production arrangements. Kodak’s emphasis on U.S. production reflects its objective of providing pharmaceutical, biotechnology and life science organizations with a more reliable domestic supply of essential products.
The company says its new normal saline solution is manufactured and aseptically filled in the United States. It also highlights product traceability and applicable USP compliance as part of the offering.
These attributes align with Kodak’s wider approach to developing a portfolio for customers that require consistent quality and transparent sourcing. As pharmaceutical supply chains continue to face demands for dependable materials, manufacturers and research organizations often assess not only product specifications but also supplier capabilities, documentation and manufacturing arrangements.
Kodak’s continued portfolio development is intended to address these considerations while establishing a stronger position in the pharmaceutical products market.
New Online Store Simplifies Purchasing for U.S. Customers
In addition to expanding its product range, Kodak has launched a dedicated online store for its U.S. pharmaceutical customers. The platform is available at and provides direct access to the company’s growing selection of pharmaceutical-grade products.
The online store is designed to make it easier for customers to identify products, review technical information and complete purchasing activities. Visitors can browse Kodak’s available buffers and reagents, compare product specifications, access supporting documentation and place orders through the platform.
For pharmaceutical manufacturers, biotechnology companies and life science organizations, access to product information is an important part of the purchasing process. Teams may need to assess specifications, confirm suitability for particular workflows and review supporting documentation before selecting materials. Bringing these resources together through a dedicated online platform can help make product discovery and procurement more convenient.
The new store also creates a direct digital channel between Kodak and its U.S. customers. Rather than relying exclusively on traditional purchasing routes, customers can use the platform to explore the available portfolio and identify products that meet their requirements.
The launch complements Kodak’s product expansion by making its growing range of pharmaceutical solutions more accessible. As the portfolio develops, the online store is expected to serve as a central purchasing destination for U.S. customers seeking Kodak’s buffers and reagents.
Customers can visit the platform at to explore available products and review the information provided for each offering.
Portfolio Growth Builds on Existing Products
KODAK Normal Saline, 0.9%, is the latest addition to a phased expansion of the company’s pharmaceutical portfolio. Kodak’s existing offerings include Water for Injection and multiple phosphate-buffered saline (PBS) formulations.
Water for Injection is an important pharmaceutical-grade water product used in applications where the relevant quality and regulatory requirements call for this type of material. PBS formulations are commonly used in laboratory and life science workflows, with their suitability depending on the specific formulation and intended use.
By expanding its range across these product categories, Kodak is seeking to provide customers with access to a broader selection of essential solutions through its pharmaceutical business. The company has also indicated that additional products are planned, demonstrating that the normal saline launch is part of a longer-term portfolio development strategy rather than an isolated introduction.
Kodak is also progressing toward the introduction of Class II products as part of its broader expansion plans. The company has not detailed all the products or timelines associated with this next phase in the announcement, but the stated direction indicates an intention to broaden its offerings further.
Continued product development could allow Kodak to serve a wider range of customer requirements across pharmaceutical manufacturing, biotechnology and life sciences. The combination of additional product categories and a direct online sales channel is intended to support customers as they evaluate and procure the materials needed for their operations.
Kodak Leadership Highlights Customer Accessibility
Jim Continenza, Executive Chairman and Chief Executive Officer of Kodak, said the product launch and the online store reflect the company’s commitment to improving access to essential pharmaceutical products.
“The launch of KODAK Normal Saline, 0.9% and our new U.S. online store reflect our commitment to making essential pharmaceutical products more accessible to customers,” Continenza said. “By combining high-quality, domestically produced solutions with a simpler way to purchase them, we are creating a stronger foundation to serve pharmaceutical, biotech, and life science organizations.”
The comments underline the two central elements of Kodak’s announcement: expanding its range of pharmaceutical products and simplifying how customers obtain them. The new saline solution broadens the company’s product offering, while the online store provides a digital channel through which customers can explore products and place orders.
Together, the initiatives support Kodak’s goal of developing a more comprehensive offering for organizations that rely on pharmaceutical-grade reagents and related materials. The company is emphasizing domestic manufacturing, traceability, product documentation and purchasing convenience as it continues to develop its presence in the sector.
Strengthening Kodak’s Position in Pharmaceutical and Life Science Markets
Kodak’s latest announcement marks another milestone in its effort to establish a growing pharmaceutical products business. The addition of KODAK Normal Saline, 0.9%, extends its portfolio of sterile, ready-to-use buffers and reagents, while the new U.S. online store creates a more direct route for customers to access the company’s offerings.
The strategy combines product development with improvements to the customer purchasing experience. Through its U.S.-based, FDA-registered cGMP manufacturing facility, Kodak is focusing on domestically produced products with traceability and applicable quality specifications. Its online store complements that manufacturing approach by providing access to product information, supporting documentation and ordering capabilities.
With Water for Injection, multiple PBS formulations and normal saline now included in its expanding range, Kodak plans to continue broadening its pharmaceutical portfolio. Its stated progress toward introducing Class II products further signals an ongoing effort to develop additional offerings for customers across regulated industries.
As the company advances these initiatives, its focus remains on supplying essential products to pharmaceutical, biotechnology and life science organizations while making them easier to find and purchase. The latest launch and online platform represent complementary steps in Kodak’s broader effort to build a stronger foundation in pharmaceutical manufacturing and product supply.
